MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-06, Vol.41 (S2), p.168-170
Main Authors: Sehn, L., Sarkozy, C., Song, Y., Salar, A., Trotman, J., Zinzani, P. L., Zhang, J., Zhang, W., Fustier, P., Delarue, R., Nastoupil, L.
Format: Article
Language:English
Subjects:
CD20 antigen
Lymphoma
Rituximab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3163_T04